Lupin launches generic inhalation product in US market

PTI New Delhi | Updated on June 04, 2021

The drug is to be used by nebulisation only

Drug firm Lupin on Friday said it has launched Arformoterol Tartrate, an inhalation product to treat conditions like chronic bronchitis and emphysema, in the US market.

The Mumbai-based company's product is the generic version of Sunovion Pharmaceuticals Inc's Brovana inhalation solution, Lupin said in a statement.

Also read: Lupin to enter digital healthcare space in India

Arformoterol Tartrate inhalation solution is indicated for the long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

It is for use by nebulisation only, the drugmaker noted.

Shares of Lupin were trading 0.39 per cent up at ₹1,237.20 apiece on the BSE.

Published on June 04, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor